How does investment portfolio change in pre and post epidemic era?--experience from Chinese medical and pharmaceutical industry
DOI:
https://doi.org/10.54691/bcpbm.v38i.3932Keywords:
Covid-19; Epidemic Medical and Pharmaceutical Industry; Index Model.Abstract
The exogenesis shock, the Covid-19 epidemic, is considered as a big shock in the financial market. The paper discussed how the investment portfolio comprising of the top ten medical and pharmaceutical stocks, changes before and after the break of epidemic. Three constraints are taken into consideration to provide more information to investors. Also, the Medical and Pharmaceutical Index instead of the market return ratio is considered as standard, allowing it much closer to the reality. The research finds that the investors have greater confidence on medical and pharmaceutical industry in the post-epidemic era than in the pre-epidemic era, presented by higher annualized average return and lower Sharpe ratio. The research of this paper will provide some portfolio-construction experience under the global negative shock. At the same time, it is also worth noting that this paper mainly focused on the changes of portfolios with the aim of creating the maximum Sharpe ratio and the minimum standard deviation under certain constraints, whose results showed that the market are having growing confidence in the medical and pharmaceutical industry in the post-epidemic era and more capital is flowing to the corporations with out-standing performance in the anti-epidemic period.
Downloads
References
Overseas Net: Digital reading of the global epidemic on March 9: more than 1.63 million cases were confirmed worldwide, with a total of more than 450 million deaths in the United States, accounting for as high as 16%[EB/OL]. [2022-03-12]
https://baijiahao.baidu.com/s?id=1726865316850596556&wfr=spider&for=pc.
Maureen O' Hara & Xing (Alex)Zhou: Anatomy of a liquidity crisis: Corporate bonds in the COVID-19 crisis, Journal of Financial Economic,2021, 142(1): 46-68.
Zhiguo He, Stefan Nagel &Zhaogang Song: Treasury inconvenience yields during the COVID-19 crisis, Journal of Financial Economics, 143(1): 57-79.
Ralph S.J. Koijen &Motohiro Yogo: The Fragility of Market Risk Insurance, Journal of Finance, 2022, 77(2): 815-862.
Ivo Welch: The Wisdom of the Robinhood Crowd, Journal of Finance, 2022, 77(3): 1489-1527.
Ding, W., Levine, R., Lin, C., & Xie, W. (2021). Corporate immunity to the COVID-19 pandemic. Journal of Financial Economics, 141(2): 802.
Patrick Augustin, Valeri Sokolovski, Marti G. Subrahmanyam & Davide Tomio: In sickness and in debt: The COVID-19 impact on sovereign credit risk, Journal of Financial Economic, 2022, 143(3): 1251-1274.
E. J. Elton, M. J. Gruber, and M. W. Padberg. “Simple Criteria for Optimal Portfolio Selection.” The Journal of Finance 11 (December 1976), 1341–57.
E. J. Elton, M. J. Gruber, and M. W. Padberg. “Simple Rules for Optimal Portfolio Selection: The Multi-Group Case.” Journal of Financial and Quantitative Analysis 12 (September 1977), 329–45.
K. J. Cohen and J. A. Pogue. “An Empirical Evaluation of Alternative Portfolio Selection Models.” Journal of Business 40 (April 1967), 166–93.
K. V. Smith. “Stock Price and Economic Indexes for Generating Efficient Portfolios,” The Journal of Business, 42 (April, 1969), pp. 326–336.






